Ratziua V, Bellentanib S, Cortez-Pintoc H, Dayd C, Marchesinie G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol. 2010;53:372–84. https://www.journal-of-hepatology.eu/action/showPdf?pii=S0168-8278%2810%2900414-9

Rinella ME. Examining the nomenclature change from NAFLD and NASH to MASLD and MASH. Gastroenterol Hepatol (NY). 2023;19:697–9. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10882866/pdf/GH_19_11_697.pdf

Google Scholar 

Ekstedt M, Franzen LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006;44:865–73. https://doi.org/10.1002/hep.21327

Article  CAS  PubMed  Google Scholar 

Lichtenstein GR. Shifting our focus from NASH to MASH. Gastroenterol Hepatol (N. Y). 2023;19:511 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10524405/pdf/GH_19_9_511.pdf

PubMed  Google Scholar 

Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79 j:1542–56. https://www.journal-of-hepatology.eu/action/showPdf?pii=S0168-8278%2823%2900418-X December

Article  Google Scholar 

American Association for the Study of Liver Diseases. New MASLD Nomenclature. 2023. https://www.aasld.org/new-masld-nomenclature

Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med. 2010;363:1341–50. https://www.nejm.org/doi/pdf/10.1056/NEJMra0912063?articleTools=true

Article  CAS  PubMed  Google Scholar 

Tomah S, Alkhouri N, Hamdy O. Nonalcoholic fatty liver disease and type 2 diabetes: where do diabetologists stand? Clin Diabetes Endocrinol. 2020;6:9 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7275502/pdf/40842_2020_Article_97.pdf

Article  PubMed  PubMed Central  Google Scholar 

Diehl AM, Day C. Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis. N Engl J Med. 2017;377:2063–72. https://www.nejm.org/doi/pdf/10.1056/NEJMra1503519?articleTools=true

Article  CAS  PubMed  Google Scholar 

Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67:328–57. https://journals.lww.com/hep/fulltext/2018/01000/the_diagnosis_and_management_of_nonalcoholic_fatty.31.aspx

Article  PubMed  Google Scholar 

REZDIFFRA (resmetirom) tablets, for oral use Initial U.S. Approval: 14March 2024 (Drug Label) https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217785s000lbl.pdf

Afdhal NH. Fibroscan (transient elastography) for the measurement of liver fibrosis. Gastroenterol Hepatol (N. Y). 2012;8:605–7. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3594956/pdf/GH-08-605.pdf

PubMed  Google Scholar 

Ajmera V, Loomba R. Imaging biomarkers of NAFLD, NASH, and fibrosis. Mol Metab. 2021;50:101167 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8324681/pdf/main.pdf

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zeng Y, He H, An Z. Advance of serum biomarkers and combined diagnostic panels in nonalcoholic fatty liver disease. Dis Markers. 2022;2022:1254014 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9259243/pdf/DM2022-1254014.pdf

Article  PubMed  PubMed Central  Google Scholar 

A Brief History of the Center for Drug Evaluation and Research. 01/31/2018. https://www.fda.gov/about-fda/fda-history-exhibits/brief-history-center-drug-evaluation-and-research

FDA Center for Drug Evaluation Director-designate Carl Peck. PINK SHEET 05 Oct 1987. https://scrip.citeline.com/PS012562/FDA-Center-for-Drug-Evaluation-Director-designate-Carl-Peck

Drug and Biological Product Consolidation. Federal Register / Vol. 68, No. 123 / Thursday, June 26, 2003 / Notices. https://www.govinfo.gov/content/pkg/FR-2003-06-26/pdf/03-16242.pdf

FDA Office of New Drugs (OND) Annual Report (2022). https://www.fda.gov/media/172747/download?attachment

CFR - Code of Federal Regulations Title 21. INVESTIGATIONAL NEW DRUG APPLICATION. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRsearch.cfm?CFRPart=312

Personal Communication, Brian E Harvey MD PhD. March 17, 2024

Modernizing FDA’s New Drugs Regulatory Program. 12/05/2023 https://www.fda.gov/drugs/regulatory-science-research-and-education/modernizing-fdas-new-drugs-regulatory-program

Division of Hepatology and Nutrition (DHN). 08/11/2020. https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/office-immunology-and-inflammation-division-hepatology-and-nutrition-dhn

Statement from FDA Commissioner Scott Gottlieb, M.D., on proposed modernization of FDA’s drug review office. June 04, 2018. https://www.fda.gov/news-events/press-announcements/statement-fda-commissioner-scott-gottlieb-md-proposed-modernization-fdas-drug-review-office

FDA Guidance for Industry Expedited Programs for Serious Conditions – Drugs and Biologics. May 2014. https://www.fda.gov/media/86377/download

Breakthrough Therapy Designation. 01/04/2018. https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/breakthrough-therapy

Fast Track. 01/04/2018. https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/fast-track

Priority Review. 01/04/2018. https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/priority-review

Accelerated Approval. 02/24/2023. https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/accelerated-approval

Beakes-Read G, Neisser M, Frey P, Guarducci M. Analysis of FDA’s accelerated approval program performance december 1992–december 2021. Ther Innov Regul Sci. 2022;56:698–703. https://doi.org/10.1007/s43441-022-00430-z

Article  PubMed  PubMed Central  Google Scholar 

Accelerated Approval Update under Food and Drug Omnibus Report Act of 2022 (FDORA). https://www.congress.gov/117/bills/hr2617/BILLS-117hr2617enr.pdf

Final Decision on the Proposal to Withdraw Approval of Pepaxto (melphalan flufenamide) for Injection Docket No. FDA-2023-N-3167 February 23, 2024. https://www.fda.gov/media/176510/download?attachment

FDA issues final decision to withdraw approval of Pepaxto (melphalan flufenamide). 02/23/2024. https://www.fda.gov/drugs/drug-safety-and-availability/fda-issues-final-decision-withdraw-approval-pepaxto-melphalan-flufenamide

Endpoints and clinical trial design for nonalcoholic steatohepatitis. (AASLD 2009 Workshop Endpoints in Nonalcoholic Steatohepatitis). Hepatology. 2011;54:344–53. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4014460/pdf/nihms289374.pdf

Google Scholar 

FDA Guidance Noncirrhotic Nonalcoholic Steatohepatitis With Liver Fibrosis: Developing Drugs for Treatment (Draft). December 2018. https://www.fda.gov/media/119044/download

Filozof C, Chow SC, Dimick‐Santos L, Chen YF, Williams RN, Goldstein BJ, et al. Clinical endpoints and adaptive clinical trials in precirrhotic nonalcoholic steatohepatitis: Facilitating development approaches for an emerging epidemic. Hepatol Commun. 2017;1:577–85. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5721443/pdf/HEP4-1-577.pdf

Article  PubMed  PubMed Central  Google Scholar 

Reorganization of the Office of New Drugs with Corresponding Changes to the Office of Translational Sciences and the Office of Pharmaceutical Quality. 05/21/2020. https://www.fda.gov/drugs/regulatory-science-research-and-education/reorganization-office-new-drugs-corresponding-changes-office-translational-sciences-and-office

Nonalcoholic Steatohepatitis with Compensated Cirrhosis: Developing Drugs for Treatment Guidance for Industry (Draft). June 2019. https://www.fda.gov/media/127738/download

Madrigal Pharmaceuticals Announces the Initiation of a Phase 2 Study of MGL-3196 in Patients with Non-alcoholic Steatohepatitis (NASH) October 20, 2016 https://ir.madrigalpharma.com/node/8641/pdf

NCT02912260. Phase 2 Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis (NASH). https://classic.clinicaltrials.gov/ct2/show/NCT02912260?term=NCT02912260&draw=2&rank=1

Madrigal Pharmaceuticals Completes Enrollment in Phase 2 Proof-of-Concept Study with MGL-3196 for Treatment of NASH. August 21, 2017. https://ir.madrigalpharma.com/node/12566/pdf

Madrigal’s MGL-3196 Achieves Liver Biopsy Endpoints in Patients with Non-alcoholic Steatohepatitis (NASH) at 36 Weeks in Phase 2 Clinical Trial. May 31, 2018. https://ir.madrigalpharma.com/node/12791/pdf

Madrigal Pharmaceuticals Announces Publication in The Lancet of Positive Phase 2 Results for Resmetirom (MGL-3196) for the Treatment of Non-alcoholic Steatohepatitis (NASH). November 11, 2019. https://ir.madrigalpharma.com/node/13201/pdf

Harrison SA, Bashir MR, Guy CD, Zhou R, Moylan CA, Frias JP, et al. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2019;394:2012–24. https://www.natap.org/2022/HCV/PIIS01406736193251762.pdf Nov 30

Article  CAS  PubMed  Google Scholar 

Madrigal Pharmaceuticals Initiates Phase 3, Multinational, Double-Blind, Randomized, Placebo-Controlled Study of MGL-3196 (resmetirom) in Patients With Non-Alcoholic Steatohepatitis (NASH) and Fibrosis to Resolve NASH and Reduce Progression to Cirrhosis March 28, 2019. https://ir.madrigalpharma.com/node/13036/pdf

NCT03900429. A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis (MAESTRO-NASH). https://classic.clinicaltrials.gov/ct2/show/NCT03900429?term=Resmetirom&draw=2&rank=4

Madrigal Pharmaceuticals Announces First Patient Dosed in MAESTRO-NAFLD-1, a Second Phase 3 Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of Resmetirom (MGL-3196) in Patients With Non-Alcoholic Steatohepatitis (NASH) and Presumed NASH. December 18, 2019. https://ir.madrigalpharma.com/node/13251/pdf

NCT04197479. A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease Patients (MAESTRO-NAFLD1). https://classic.clinicaltrials.gov/ct2/show/NCT04197479?term=Resmetirom&draw=2&rank=1

Madrigal Pharmaceuticals Completes Enrollment of the 52 Week Liver Biopsy Patient Population in the Phase 3 MAESTRO-NASH Study of Resmetirom. June 30, 2021. https://ir.madrigalpharma.com/node/13726/pdf

Madrigal Pharmaceuticals Offers Patients Resmetirom in a Planned Open Label Active Treatment Extension of the Phase 3 MAESTRO-NAFLD-1 Clinical Study. July 13, 2021. https://ir.madrigalpharma.com/node/13736/pdf

NCT04951219. A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE). https://classic.clinicaltrials.gov/ct2/show/NCT04951219?term=Resmetirom&draw=2&rank=2

Positive Topline Phase 3 MAESTRO-NAFLD-1 Data Demonstrate Resmetirom was Safe, Well-Tolerated and Provided Statistically Significant Improvements in Key Measures of Liver and Cardiovascular Health. January 31, 2022. https://ir.madrigalpharma.com/node/14121/pdf

Madrigal Pharmaceuticals Initiates the MAESTRO-NASH Outcomes Study Evaluating Resmetirom for the Treatment of Patients with Compensated NASH Cirrhosis. August 31, 2022. https://ir.madrigalpharma.com/node/14471/pdf

NCT05500222. A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES). https://classic.clinicaltrials.gov/ct2/show/NCT05500222?term=Resmetirom&draw=2&rank=3

Madrigal Announces Positive Topline Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of NASH and Liver Fibrosis. December 19, 2022. https://ir.madrigalpharma.com/node/14516/pdf

Madrigal Receives Breakthrough Therapy Designation from FDA for Resmetirom and Completes Enrollment of the Phase 3 MAESTRO-NASH Biopsy Trial. April 18, 2023. https://ir.madrigalpharma.com/node/14701/pdf

Madrigal Pharmaceuticals Announces NDA Acceptance and Priority Review of the New Drug Application for Resmetirom for the Treatment of NASH with Liver Fibrosis. September 13, 2023. https://ir.madrigalpharma.com/node/14951/pdf

Madrigal Pharmaceuticals Announces Publication of the Phase 3 MAESTRO-NASH Trial of Resmetirom in the New England Journal of Medicine. February 8, 2024. https://ir.madrigalpharma.com/node/15291/pdf

Harrison SA, Bedossa P, Guy CD, Schattenberg JM, Loomba R, Taub R, et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N Engl J Med. 2024;390:497–509. https://doi.org/10.1056/NEJMoa2309000

Article  PubMed  Google Scholar 

Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Moderate to Advanced Liver Fibrosis. March 14, 2024. https://ir.madrigalpharma.com/node/15401/pdf

FDA LETTER. NDA 217785 ACCELERATED APPROVAL. March 14, 2024. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/217785Orig1s000ltr.pdf

Division of Cardiology and Nephrology https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/office-cardiology-hematology-endocrinology-and-nephrology-ochen-division-cardiology-and-nephrology

Division of Diabetes, Lipid Disorders, and Obesity